Scientech Research Llc owns $1.07 million in Eli Lilly and Company (NYSE:LLY)

VaselineSeptember 29, 2024

0 3 minutes read

Eli Lilly and Company logo Scientech Research LLC lessened its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 53.1% in the second quarter, Holdings Channel.com reports. The fund owned 1,182 shares of the company’s stock after selling 1,338 shares during the period. Scientech Research LLC’s holdings in Eli Lilly and Company were worth $1,070,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have recently made changes to their positions in the company. Capital Planning LLC acquired a new stake in shares of Eli Lilly and Company in the first quarter worth $262,000. CHURCHILL MANAGEMENT Corp purchased a new position in shares of Eli Lilly and Company in the first quarter valued at approximately $6,916,000. M&G Plc bought a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $8,896,000. HighPoint Advisor Group LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $9,878,000. Finally, Leo Wealth LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at about $3,355,000. 82.53% of shares are owned by institutional investors and hedge funds.

Insider buying and selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 8,848 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $915.31, for a total value of $8,098,662.88. Following the completion of the transaction, the insider now owns 97,299,772 shares in the company, valued at approximately $89,059,454,309.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC’s website. Over the last three months, insiders have sold 423,559 shares of company stock worth $393,136,808. 0.13% of shares are owned by company insiders.

Changes in Analyst Ratings

Want more great investment ideas?

Several analysts have recently commented on the stock. BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Truist Financial reiterated a “buy” rating and set a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Guggenheim boosted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The company currently has an average rating of “Moderate Buy” and a consensus price target of $977.35, according to MarketBeat.com.

Read our latest report on LLY

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $877.50 on Friday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11, and a quick ratio of 0.87. The firm has a 50-day moving average of $896.10 and a 200-day moving average of $842.91. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53. The company has a market cap of $833.98 billion, a P/E ratio of 129.23, a P/E/G ratio of 2.78 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY – Get Your Free Report ) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. equities research analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops and markets human pharmaceutical products worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R and Humulin U-500 for diabetes; Jardiance, Mounjaro and Trulicity for type 2 diabetes; and Zepbound for obesity.